Skip to content
Review Open access

PEGylated PLGA Nanoformulations For Effective Immunomodulatory Actors In Non–Small Cell Lung Cancer

Aug 2026 · International Journal of Nanomedicine · Vol 21, pp. 1-18 · 0 citations · 117 references
Medicine

TL;DR

Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.

Abstract

Abstract PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles have attracted increasing attention as a versatile and biocompatible nanoplatform for non-small cell lung cancer (NSCLC) therapy. Benefiting from prolonged circulation time, controllable drug-release behavior, and flexible surface modification, PEG-PLGA nanocarriers can effectively enhance tumor accumulation while reducing systemic toxicity. Recent advances indicate that PEG-PLGA nanoparticles not only improve the delivery efficiency of chemotherapeutic agents but also enable active tumor targeting through ligand conjugation and contribute to the regulation of the tumor immune microenvironment. In particular, these nanoplatforms have shown promising potential in enhancing antigen presentation, alleviating immunosuppression, and synergizing with immunotherapeutic strategies such as immune checkpoint blockade. Nevertheless, several challenges remain for clinical translation, including large-scale manufacturing, formulation reproducibility, and regulatory considerations. Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.

Read PDF

Similar papers

Review Open access Sep 2026

Sustained-release PLGA-based nanoformulated solutions for drug delivery and targeting in paediatric solid and haematological malignancies

Pediatric brain tumors continue to be one of the leading causes of death among children due to cancer because of the inadequacies of existing treatments, which include poor tumor selectivity, poor permeability across the blood-brain barrier, resistance to treatment, and high levels of side effects on developing tissu...

Rupali Verma, Shreya Kaul, Neha Jain et al. · 0 citations
Review Aug 2026

PEGylated Liposomal Nanocarriers in Cancer Therapy: Emerging Strategies and Clinical Prospects.

PEGylation has been shown to extend the circulatory lifetime, enhance drug deposition in tumors, and minimize off-target toxicity, and more effective design solutions should be employed, including stimuli-responsive liposomes and patient-tailored methods.

Ashish Kumar, Md Moidul Islam, Moidul Islam Judder et al. · 0 citations
Review Sep 2026

Recent Advances in Polymeric Nanocarriers for Breast Cancer Drug Delivery

Breast cancer remains a major global health concern, highlighting the need for advanced drug delivery strategies that can improve therapeutic efficacy while minimizing systemic toxicity. Although several reviews have discussed polymeric nanocarriers for breast cancer therapy, many have primarily focused on specific p...

Nazanin Amiryaghoubi, B. Kim · 0 citations
Review Sep 2026

Emerging biodegradable nanomaterials for innovative tumor immunotherapy.

The biodegradable nanomaterials exhibit promising potential for tumor immunotherapy due to their unique advantages including biodegradability, simple and cost-effective synthesis, and use of renewable resources, aligning with environmental and sustainable development goals.

Ru-Tuan Dong, Shuai-Shuai Ding, Bo-Kai Song et al. · 1 citation
Review Sep 2026

Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives

Overall, this review provides a comprehensive overview of the design, synthesis, functionalization, therapeutic applications, pharmacokinetics, biodistribution, safety profiles, and clinical translation potential of folate-functionalized chitosan NPs for precision cancer therapy.

Mohammad Sameer Khan, W. Almalki · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.